About Ultragenyx Pharmaceutical Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ultragenyx.com/
Frequently Asked Questions
What is the 52-week range for RARE?
The 52-week high is $39.8899 and the 52-week low is $12.73.
What is the P/E ratio for RARE?
The P/E ratio data is currently unavailable.
What is the dividend yield for RARE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -414.17%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -81.73%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 15.22.
Analyst Recommendation Trends
Wall Street analyst consensus for RARE over the last few months:
Latest RARE News
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. EMA validation confirms that the application is sufficiently complete for the Agency to begin its formal scientific review. Validation
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results
Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month.
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) just added another commercial product to its portfolio. The FDA on September 17 approved Fayuvi for the treatment of neurologic manifestations of Sanfilippo syndrome Type A in pediatric patients with preserved neurodevelopmental function. Fayuvi becomes the first approved treatment for this rare and fatal childhood disorder. Ultragenyx stock jumped more than […]
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18
Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
/C O R R E C T I O N -- Andelyn Biosciences/
Andelyn Biosciences ("Andelyn"), a leading, patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), today announced it is now manufacturing FAYUVI™ (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy, for commercial supply at its Columbus, Ohio facility. The announcement follows the U.S. Food and Drug Administration's approval of Ultragenyx Pharmaceutical Inc.'s FAYUVI™ for treating Sanfilippo syndrome type A, also known as mucopolysacchari
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20
Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $18 to $20.
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy
Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest
FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $39
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $33 to $39.
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A September 17, 2026 5:30 PM...
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending
Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved for Sanfilippo syndrome Type A.
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy
The Food and Drug Administration (FDA) granted full approval of Fayuvi, also known as UX111, for pediatric patients.
Ultragenyx Stock Jumps on Landmark FDA Approval
The biopharmaceutical company received FDA approval for a first-of-its-kind treatment for a rare neurodevelopmental disease.
How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive
Ultragenyx Pharmaceuticals won approval for its newest gene therapy on Thursday, helping shares partially reverse a catastrophic dive.
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A Ultragenyx’s UltraCare® program will support access, and commercial product is expected to be available to ship to Qualified Treatment Centers within 30-60 days FAYUVI marks the second gene therapy approval, and sixth FDA approval overall, for Ultragenyx The Company received a Priority R
Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M
https://event.choruscall.com/mediaframe/webcast.html?webcastid=1t78iDYA
Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares
RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan
In early September 2026, Ultragenyx Pharmaceutical announced that its Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary and key secondary cognitive and functional endpoints, prompting a review of the program and planned significant expense reductions. On the same day, the FDA confirmed that Ultragenyx’s newly approved GENGLYCOS gene therapy for glycogen storage disease type Ia qualifies for a rare pediatric disease priority review voucher,...
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback
Ultragenyx Pharmaceutical stock is under pressure after a multi year slide in returns, yet current market multiples still screen as expensive and the broader valuation checks send a mixed message. With fresh clinical setbacks alongside some positive data elsewhere in the pipeline, investors face conflicting signals about what the current price really reflects. Over the past 5 years the share price has fallen about 85%, which points to a sharp reset in market expectations for Ultragenyx...
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.
This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Analysts downgraded UiPath, Cal-Maine with several price-target cuts.
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $43 to $32.
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.
Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows?
NIO, Ultragenyx Pharmaceutical and McDonald's slipped to annual lows on Thursday amid company-related pressures and Wall Street pessimism around the stocks.
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.
Ultragenyx's 'Fall From Grace' — Shares Crash 44%, Hitting A Record Low
Ultragenyx stock crashed Thursday, losing almost half its value, after its experimental Angelman treatment failed in final-phase testing.
Nvidia, Tesla, Robinhood, Snowflake, Ultragenyx, Ciena, and More Stocks That Explain Today’s Market
Nvidia stock rises on a deal for it to acquire Hugging Face while Tesla sadvances ahead of an important Cybercab event.
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36
JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.
Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28
Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $77 to $28.
Thursday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.
Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist
Ultragenyx shares plunged after its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet key endpoints. Click for an analysis on RARE.
Ultragenyx mulls fate of rare disease programme on Phase III flop
Following the late-stage miss, analysts raise concerns around potential readthrough to another ongoing study in Angelman syndrome involving apazunersen.
Gapping stocks in Thursday's session
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies (NASDAQ:BIAF)
Wondering what's happening in today's pre-market session?
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28
Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $58 to $28.
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Gold Jumps 3%; ISM Services PMI Rises In August
U.S. stocks climbed, led by Dow’s 600-point gain; services PMI strengthened, Snowflake surged, while Ultragenyx plunged 44%.
TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $18
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $49 to $18.
Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint
Ultragenyx (NASDAQ:RARE) shares fell 44. 7% to $14.
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.
RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead
William Blair downgraded Ultragenyx to ‘Market Perform’ from ‘Outperform,’ stating the miss could have negative implications for Ultragenyx’s other Angelman syndrome trial.
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $18
Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $50 to $18.
Premarket movers: Snowflake, Five Below surge after strong earnings
Investing.com -- U.S. equity futures were mixed early Thursday, a day after major averages snapped a three-day losing streak driven by rising Treasury yields amid renewed U.S.-Iran hostilities. S&P 500 futures were up 0.1%, Dow futures rose 0.2%, and Nasdaq 100 futures climbed 0.1%.
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $37
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $83 to $37.
Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $23
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $30 to $23.
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
Ultragenyx reports Phase 3 Aspire study of apazunersen failed to meet primary endpoints, prompting plans for expense cuts.
This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts revised price targets for Ultragenyx, UiPath, Netskope, Snowflake, Magnite, Broadcom, CrowdStrike and Moderna; ratings largely maintained.
Evercore ISI Group Downgrades Ultragenyx Pharmaceutical to In-Line, Lowers Price Target to $16
Evercore ISI Group analyst Liisa Bayko downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to In-Line and lowers the price target from $34 to $16.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares increased by
NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. futures rose, but NetApp fell 8.2% after earnings. Ultragenyx plunged 45% on a failed trial; HPE, Methode and others also traded lower premarket.
Baird Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $16
Baird analyst Joel Beatty downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to Neutral and lowers the price target from $40 to $16.
Market-Moving News for September 3rd
AVGO: -5% | AVGO stock has given up its prior loss. Broadcom shares were trading lower after the company reported Q3 financial results and issued Q4 sales guidance below estimates. SNOW: -23% | Snowflake shares are
HC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $25
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $50 to $25.
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $33
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $103 to $33.
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Huizenga Theodore Alan | -1,283 | $13.57 | $17,410 |
| 2026-09-03 | Huizenga Theodore Alan | -161 | $13.99 | $2,252 |
| 2026-08-03 | Parschauer Karah Herdman | -1,900 | $24.92 | $47,348 |
| 2026-08-03 | Horn Howard | -4,696 | $24.92 | $117,024 |
| 2026-07-01 | Horn Howard | -4,698 | $33.13 | $155,645 |
| 2026-06-15 | Sanders Corazon (Corsee) D. | -2,000 | $25.05 | $50,100 |
| 2026-06-15 | Parschauer Karah Herdman | -1,899 | $24.62 | $46,753 |
| 2026-06-01 | Horn Howard | -4,653 | $23.77 | $110,602 |
| 2026-05-18 | SULIMAN SHEHNAAZ | -5,740 | $25.12 | $144,189 |
| 2026-05-14 | Ray Amrit | +14,058 | - | - |
| 2026-05-14 | Ray Amrit | +7,751 | - | - |
| 2026-05-14 | Sanders Corazon (Corsee) D. | +14,058 | - | - |
| 2026-05-14 | Sanders Corazon (Corsee) D. | +7,751 | - | - |
| 2026-05-14 | SULIMAN SHEHNAAZ | +14,058 | - | - |
| 2026-05-14 | SULIMAN SHEHNAAZ | +7,751 | - | - |
| 2026-05-14 | Fust Matthew K | +14,058 | - | - |
| 2026-05-14 | Fust Matthew K | +7,751 | - | - |
| 2026-05-14 | NARACHI MICHAEL | +14,058 | - | - |
| 2026-05-14 | NARACHI MICHAEL | +7,751 | - | - |
| 2026-05-14 | Dunsire Deborah | +14,058 | - | - |
| 2026-05-14 | Dunsire Deborah | +7,751 | - | - |
| 2026-05-14 | WELCH DANIEL G | +14,058 | - | - |
| 2026-05-14 | WELCH DANIEL G | +7,751 | - | - |
| 2026-05-05 | Crombez Eric | -344 | $24.96 | $8,586 |
| 2026-05-01 | Horn Howard | -4,683 | $24.9 | $116,607 |
| 2026-04-22 | Huizenga Theodore Alan | +7,348 | - | - |
| 2026-04-22 | Huizenga Theodore Alan | +20,241 | - | - |
| 2026-04-16 | Huang Dennis Karl | +79,936 | - | - |
| 2026-04-16 | Huang Dennis Karl | +23,116 | - | - |
| 2026-04-16 | Pinion John Richard | +79,936 | - | - |
| 2026-04-16 | Pinion John Richard | +23,116 | - | - |
| 2026-04-16 | Parschauer Karah Herdman | +49,960 | - | - |
| 2026-04-16 | Parschauer Karah Herdman | +28,895 | - | - |
| 2026-04-16 | Harris Erik | +49,960 | - | - |
| 2026-04-16 | Harris Erik | +28,895 | - | - |
| 2026-04-16 | Crombez Eric | +59,952 | - | - |
| 2026-04-16 | Crombez Eric | +34,674 | - | - |
| 2026-04-16 | Horn Howard | +59,952 | - | - |
| 2026-04-16 | Horn Howard | +34,674 | - | - |
| 2026-04-16 | KAKKIS EMIL D | +132,693 | - | - |
| 2026-04-16 | KAKKIS EMIL D | +76,745 | - | - |
| 2026-04-01 | Horn Howard | -4,683 | $20.97 | $98,203 |
| 2026-03-10 | Parschauer Karah Herdman | -3,508 | $22.67 | $79,526 |
| 2026-03-06 | Parschauer Karah Herdman | -6,018 | $21.4 | $128,785 |
| 2026-03-03 | Horn Howard | -1,635 | $22.4 | $36,624 |
| 2026-03-02 | Pinion John Richard | -10,029 | $22.8 | $228,661 |
| 2026-03-02 | Harris Erik | -10,539 | $22.8 | $240,289 |
| 2026-03-02 | Parschauer Karah Herdman | -8,135 | $22.8 | $185,478 |
| 2026-03-02 | Huizenga Theodore Alan | -1,632 | $22.8 | $37,210 |
| 2026-03-02 | Huizenga Theodore Alan | -148 | $23.39 | $3,462 |
| 2026-03-02 | Horn Howard | -3,119 | $22.54 | $70,302 |
| 2026-03-02 | Horn Howard | -5,290 | $22.8 | $120,612 |
| 2026-03-02 | Crombez Eric | -7,029 | $22.8 | $160,261 |
| 2026-03-02 | Huang Dennis Karl | -999 | $23.39 | $23,367 |
| 2026-03-02 | KAKKIS EMIL D | -54,404 | $22.8 | $1,240,411 |
| 2026-03-01 | Pinion John Richard | +11,137 | - | - |
| 2026-03-01 | Harris Erik | +11,643 | - | - |
| 2026-03-01 | Parschauer Karah Herdman | +11,137 | - | - |
| 2026-03-01 | Horn Howard | +6,143 | - | - |
| 2026-03-01 | Crombez Eric | +11,643 | - | - |
| 2026-03-01 | Huang Dennis Karl | +11,137 | - | - |
| 2026-03-01 | KAKKIS EMIL D | +71,177 | - | - |
| 2026-02-02 | Horn Howard | -3,061 | $23.56 | $72,117 |
| 2026-01-02 | Horn Howard | -3,150 | $22.84 | $71,946 |
| 2025-12-29 | Huizenga Theodore Alan | -85 | $34.38 | $2,922 |
| 2025-12-10 | Horn Howard | -3,081 | $36.38 | $112,087 |
| 2025-10-13 | Horn Howard | -7,942 | $31.51 | $250,252 |